Aboleris Pharma

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren's Disease at EULAR 2026 Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands,

AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis ABO21009's unique mechanism of action depletes pathogenic Effector T and B cells while inducing expansion of Regu

AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, announced today that the first patient has been dosed with ABO21009, a humanized anti-

AbolerIS Pharma Announces Publication in Molecular Therapy Cell Press Journal of New Preclinical Results Supporting Mechanism of Action of ABO21009, a First-in-Class Anti-CD45RC Antibody, Currently in Phase 1 -Results highlight the potential to transform

/PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune...

Aboleris Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer Gosselies, Belgium and Nantes, France, October 30, 2025 /PRNewswire/ - AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to

/PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune...

Date 11 - 14 June 2025 Location Barcelona,Spain The EULAR European Congress of Rheumatology is an esteemed flagship event, consistently delivering an unparalleled experience year after year. The Congress serves as a unifying platform where individuals wit